Volume 15, Issue 9 pp. 755-761

Economic evaluation of ondansetron vs dimenhydrinate for prevention of postoperative vomiting in children undergoing strabismus surgery

CHARLES PIWKO PhD

CHARLES PIWKO PhD

Department of Health Policy, Management and Evaluation, University of Toronto

Department of Clinical Pharmacology, The Hospital for Sick Children

Search for more papers by this author
ARIELLE LASRY MSc

ARIELLE LASRY MSc

Department of Mechanical and Industrial Engineering, University of Toronto

Search for more papers by this author
KHALED ALANEZI MD

KHALED ALANEZI MD

Department of Health Policy, Management and Evaluation, University of Toronto

Search for more papers by this author
PETER C. COYTE PhD

PETER C. COYTE PhD

Department of Health Policy, Management and Evaluation, University of Toronto

CHSRF/CIHR Health Services Chair

Search for more papers by this author
WENDY J. UNGAR PhD

WENDY J. UNGAR PhD

Department of Health Policy, Management and Evaluation, University of Toronto

Population Health Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada

Search for more papers by this author
First published: 23 May 2005
Citations: 9
Dr Wendy J. Ungar, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8 (email: [email protected]).

Summary

Background : Although rarely life-threatening, postoperative vomiting (POV) is a distressing complication. The incidence of POV ranges from 34 to 90% in children undergoing strabismus surgery when antiemetics are not administered prophylactically.

Methods : In this study, a cost-consequence analysis (CCA) is used to estimate the economic benefit of ondansetron and dimenhydrinate as antiemetics administered prophylactically in children undergoing strabismus surgery. This retrospective study was conducted at The Hospital for Sick Children based on a review of 70 charts.

Results : Ondansetron was more effective with 45.3 POV-free patients (PFP) in an adjusted cohort of 100, while dimenhydrinate resulted in 38.2 PFP in an adjusted cohort of 100. The costs were significantly different between the two groups, CAD$ 185.90 (±26.37, 95% CI, CAD$ 173,89; CAD$ 197.90) and CAD$ 232.90 (±CAD$ 66.84, 95% CI, CAD$ 198.53; CAD$ 267.27) per patient for ondansetron and dimenhydrinate, respectively. The length of stay in the postanesthetic care unit (PACU) represented over 97% of total costs, and the mean lengths of stay in the PACU for ondansetron and dimenhydrinate were significantly different, 3.43 and 4.41 h, respectively.

Conclusion : This study should serve as a pilot for a large-scale investigation on the correlation between the length of stay in the PACU and the antiemetic agent used.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.